34.90
34.90 (0%)
As of Feb 14, 2025
BridgeBio Pharma, Inc. [BBIO]
Source:
Company Overview
BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials.
| Country | United States |
| Headquarters | palo alto, california |
| Phone Number | (650) 391-9740 |
| Industry | manufacturing |
| CEO | Neil Kumar |
| Website | bridgebio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $221.9 |
| Operating Profit | $-593 |
| Net Income | $-543.3 |
| Net Cash | $288.5 |
Profit Ratios
| Gross Margin | $218 |
| Operating Margin | -267.2 |
| Profit as % of Revenues | -40.1% |
| Profit as % of Assets | -74.1% |
| Profit as % of Stockholder Equity | 37.3% |
Management Effectiveness
| Return on Equity | 37.3% |
| Return on Assets | -59.1% |
| Turnover Ratio | 30.3% |
| EBITA | $-593 |
Balance Sheet and Cash Flow Measures
| Total Assets | $919.3 |
| Total Liabilities | $2,377 |
| Operating Cash Flow | $-520.7 |
| Investing Cash Flow | $60.8 |
| Financing Cash Flow | $748.5 |
